Overall, the treatment success rate (i.e., a reduction ≥1 in PSS and ≥ 2 in PIS) was 90%. Importantly, no significant side effects of the p62-plasmid during the whole treatment period were observed.

Neuros Medical has raised$56 million to fund commercialization of its nerve stimulation system for chronic post-amputation pain, the company said Wednesday.

The TSA demonstrated that the cumulative Z-curve for the clinical effective rate, ABI, common peroneal nerve MNCV, and common peroneal nerve SNCV crossed the monitoring boundaries, indicating that the ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions caused by tissue stress and inflammation, including neuropathic pain and ...

Boston Scientific Corp. filed a federal lawsuit seeking a court’s judgment that Stryker Corp.'s release of a lower back pain treatment would infringe its patent for a similar treatment. Boston ...